검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα ORR 0.4% | ||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim | Osimertinib | Binimetinib | Gemcitabine Hydrochloride |
Overview Company | Roche / Genentech | Amgen | Janssen Research & Development, LLC | Pfizer | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | FRα | Ovarian Cancer | FRα | FRα | FRα |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer | Carcinoma, Non-Small-Cell Lung | Cancer | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona | — | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | CD20 expression | PD-L1-high | — | PD-L1 expression | HER2 expression |
PK/PD Half-life | 12.2 h | 80 days | 48 h | 64 h | — |
PK/PD Species | Rat | Cynomolgus monkey, NHP | — | Rat | Mouse |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP | — | Rat, In vitro | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | — | PK | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, NHP, Rat | — | Rat, Rabbit | Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat | — | Rat | Mouse, In vitro |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms ind | Hepatotoxicity: Monitor liver function tests before and during treatment with MEKTOVI and e | From Parenteral to Oral Delivery: Facile Formulation of Oral Gemcitabine Nanospanlastics for Enhanced Bioavailability and Anticancer Activity in Murine Breast Cancer Model.. Gemcitabine hydrochloride (GEM) is a commonly used antineoplastic that is delivered only by intravenous infusion due to its limited oral bioavailability of 10%. The study aims to design and optimize novel Spanlastics (GEM-SLs)… |
Clinical Primary efficacy | ORR 100% | ORR 56.7% | ORR 76.7% | ORR 66.7% | ORR 0.4% |
Clinical ORR | 100.0% | 56.7% | 76.7% | 66.7% | 0.4% |
Clinical PFS | — | 10.1 | — | — | — |
Clinical OS | — | 24.6 | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT00911170 | ClinicalTrials.gov NCT02296125 | ClinicalTrials.gov NCT01543698 | ClinicalTrials.gov NCT00942331 |
Clinical Data Tier / Score | S · 92 | A · 70 | B · 69 | C · 57 | C · 41 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 5개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Gemcitabine Hydrochloride (Gemcitabine Hydrochloride) K-Group, Beta, Inc., a wholly owne…·FRα ORR 0.4% | ||||
|---|---|---|---|---|---|
Overview Program | Polatuzumab Vedotin | Pegfilgrastim | Osimertinib | Binimetinib | Gemcitabine Hydrochloride |
Overview Company | Roche / Genentech | Amgen | Janssen Research & Development, LLC | Pfizer | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc |
Overview Modality | ADC | ADC | ADC | ADC | ADC |
Overview Target | FRα | Ovarian Cancer | FRα | FRα | FRα |
Overview Indication | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Cancer; Colon Cancer | Carcinoma, Non-Small-Cell Lung | Cancer | Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 |
Overview Status | RECRUITING | RECRUITING | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functiona | — | checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting a | of ProAgio, which includes reducing hypoxia and modulating TME |
MoA Biomarker | CD20 expression | PD-L1-high | — | PD-L1 expression | HER2 expression |
PK/PD Half-life | 12.2 h | 80 days | 48 h | 64 h | — |
PK/PD Species | Rat | Cynomolgus monkey, NHP | — | Rat | Mouse |
PK/PD Animal (cat.) | Rat, In vitro | Human, NHP | — | Rat, In vitro | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | Pharmacokinetic | — | PK | pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, NHP, Rat | — | Rat, Rabbit | Mouse |
Toxicology Animal (cat.) | Mouse, Rat, NHP | Rat | — | Rat | Mouse, In vitro |
Toxicology Major finding | Hepatotoxicity: Monitor liver enzymes and bilirubin | Thrombocytopenia: Monitor platelet count ( 5 | Interstitial Lung Disease (ILD)/Pneumonitis : Monitor for new or worsening pulmonary symptoms ind | Hepatotoxicity: Monitor liver function tests before and during treatment with MEKTOVI and e | From Parenteral to Oral Delivery: Facile Formulation of Oral Gemcitabine Nanospanlastics for Enhanced Bioavailability and Anticancer Activity in Murine Breast Cancer Model.. Gemcitabine hydrochloride (GEM) is a commonly used antineoplastic that is delivered only by intravenous infusion due to its limited oral bioavailability of 10%. The study aims to design and optimize novel Spanlastics (GEM-SLs)… |
Clinical Primary efficacy | ORR 100% | ORR 56.7% | ORR 76.7% | ORR 66.7% | ORR 0.4% |
Clinical ORR | 100.0% | 56.7% | 76.7% | 66.7% | 0.4% |
Clinical PFS | — | 10.1 | — | — | — |
Clinical OS | — | 24.6 | — | — | — |
Clinical Result source | ClinicalTrials.gov NCT02611323 | ClinicalTrials.gov NCT00911170 | ClinicalTrials.gov NCT02296125 | ClinicalTrials.gov NCT01543698 | ClinicalTrials.gov NCT00942331 |
Clinical Data Tier / Score | S · 92 | A · 70 | B · 69 | C · 57 | C · 41 |
Clinical Program phase | PHASE_3 | PHASE_3 | PHASE_3 | PHASE_2 | PHASE_3 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 6일 (21일 전 · 갱신 권장) | 2026년 7월 9일 (18일 전 · 갱신 권장) | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교